Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6280 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AZD6280 | DRUG | Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects. |
| (11C) flumazenil | DRUG | Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280) |
Inclusion Criteria: * Body Mass Index (BMI) of 18-30 kg/m2 and weight of 60-100 kg * Clinically normal physical findings, medical history and laboratory values. Exclusion Criteria: * Clinically significant illness or clinical relevant trauma within 2 weeks before the study start. * History of cli...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Definium Therapeutics, Inc. | DFTX | 2 | PHASE3 | DT120 |
| Vistagen Therapeutics, Inc. | VTGN | 3 | PHASE3 | Fasedienol |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | VQW-765 |
| AbbVie, Inc. | ABBV | 1 | PHASE2 | ABBV-932 |
| Psyence Biomedical Ltd. | PBM | 1 | PHASE2 | Psilocybin therapy |
AZD6280 is an investigational small molecule developed by AstraZeneca PLC for anxiety. It is a positive allosteric modulator that acts at the GABRA2 and GABRA3 receptor subunits. It has been studied in a Phase 1 clinical trial and is not approved for any indication.
AZD6280 targets the GABRA2 and GABRA3 subunits of the GABAA receptor. It is a positive allosteric modulator, meaning it enhances the receptor's response to its natural ligand. This mechanism is being explored for anxiety, a psychiatric condition.
AZD6280 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical program for this investigational anxiety candidate.
AZD6280 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any use.
AZD6280 has been evaluated in a single completed Phase 1 trial, NCT00681746. This PET study used (11C) flumazenil to determine central GABAA receptor occupancy of AZD6280 in eight healthy male volunteers in Sweden. The trial was uncontrolled and not randomized.